HOME   |    PDF   |   


Title

A review on mTOR inhibitor use and outcomes of COVID-19 among patients with kidney transplantation

 

Authors

Sawai Singh Rathore1#,*, Vanessa Vidaurre Corrales2# , Ashwin Hassan Gopala3, Hamam Aneis4, Ibrahim Marouf Yasin Al Shyyab5, Mutaz AlBeetar5, Samah Mohamed Kannas5, Omar Jihad Saleh Almistarihi6 & Mohamed Hamed Daoud7

 

Affiliation

1Department of Internal Medicine, Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India; 2Department of Internal Medicine, Universidad Privada del Valle, Cochabamba, Bolivia; 3Department of Internal Medicine, Jinzhou Medical College, Jinzhou, China; 4Department of Internal Medicine, UPMC, Mckeesport, Pennsylvania; 5Department of Internal Medicine, University of Sharjah, Sharjah, UAE; 6Department of Internal Medicine, Fakeeh University Hospital, Dubai, UAE; 7Department of Internal Medicine, Bogomolets National Medical University, Kyiv, Ukraine; *Corresponding author, #These authors have contributed equally to this work and share first authorship

 

Email

Sawai Singh Rathore - E-mail: Sawais.rathore77@gmail.com

Vanessa Vidaurre Corrales - E-mail: vanessavidaurre23@hotmail.com

Ashwin Hassan Gopala - E-mail: iashwinhg19@gmail.com

Hamam Aneis - E-mail: Homam-1@hotmail.com

Ibrahim Marouf Yasin Al Shyyab - E-mail: ibrahimshayyab6000@yahoo.com

Mutaz AlBeetar - E-mail: Motaz.albitar@hotmail.com

Samah Mohamed Kannas - E-mail: s.kannas@outlook.com

Omar Jihah Saleh Almistarihi - E-mail: omarmist@hotmail.com

Mohamed Hamed Daoud - E-mail: Daoudmohd99@gmail.com

 

Article Type

Review

 

Date

Received June 30, 2025; Revised June 30, 2025; Accepted June 30, 2025, Published June 30, 2025

 

Abstract

Kidney transplant recipients are at increased risk of severe COVID-19 due to immunosuppression and the impact of mTOR inhibitors on outcomes remains unclear. Hence, we evaluated 24 observational studies with 5,882 kidney transplant patients to assess the association of mTOR inhibitors with COVID-19 severity and mortality. Random-effects models showed that mTOR inhibitors were significantly associated with reduced mortality (OR=0.63, 95% CI 0.48–0.83, P=0.001) but not with COVID-19 severity (OR=0.70, 95% CI 0.41–1.20, P=0.865). Thus, mTOR inhibitors may provide a survival benefit in kidney transplant patients with COVID-19, highlighting the need for further research.

 

Keywords

Kidney transplant, COVID-19, SARS-CoV-2, renal transplant; hospitalization, ICU admission, mortality, mTOR inhibitors, irolimus, everolimus, temsirolimus

 

Citation

Rathore et al. Bioinformation 21(6): 1447-1453 (2025)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.